Agilent Technologies (NYSE:A) Posts Earnings Results, Beats Estimates By $0.01 EPS

Agilent Technologies (NYSE:AGet Rating) issued its quarterly earnings results on Tuesday. The medical research company reported $1.13 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.01, MarketWatch Earnings reports. The firm had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.62 billion. Agilent Technologies had a net margin of 18.70% and a return on equity of 27.04%. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.97 EPS.

Shares of NYSE:A opened at $120.38 on Thursday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.64 and a current ratio of 2.19. The firm has a fifty day moving average price of $126.88 and a 200 day moving average price of $139.14. Agilent Technologies has a fifty-two week low of $112.64 and a fifty-two week high of $179.57. The firm has a market cap of $36.16 billion, a price-to-earnings ratio of 30.55, a P/E/G ratio of 2.80 and a beta of 1.06.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 27th. Investors of record on Tuesday, July 5th will be given a dividend of $0.21 per share. The ex-dividend date of this dividend is Friday, July 1st. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.70%. Agilent Technologies’s dividend payout ratio is 21.32%.

In related news, SVP Michael Tang sold 1,210 shares of the company’s stock in a transaction on Friday, March 18th. The shares were sold at an average price of $136.21, for a total transaction of $164,814.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Institutional investors and hedge funds have recently made changes to their positions in the company. EverSource Wealth Advisors LLC purchased a new position in Agilent Technologies in the 4th quarter worth about $31,000. Penserra Capital Management LLC bought a new position in Agilent Technologies during the 1st quarter worth about $60,000. Ironwood Wealth Management LLC. grew its holdings in Agilent Technologies by 142.5% during the 2nd quarter. Ironwood Wealth Management LLC. now owns 485 shares of the medical research company’s stock worth $72,000 after acquiring an additional 285 shares in the last quarter. Covestor Ltd grew its holdings in Agilent Technologies by 171.0% during the 1st quarter. Covestor Ltd now owns 1,241 shares of the medical research company’s stock worth $164,000 after acquiring an additional 783 shares in the last quarter. Finally, Brown Brothers Harriman & Co. grew its holdings in Agilent Technologies by 169.5% during the 1st quarter. Brown Brothers Harriman & Co. now owns 1,237 shares of the medical research company’s stock worth $164,000 after acquiring an additional 778 shares in the last quarter.

A has been the topic of several recent research reports. Evercore ISI reduced their target price on shares of Agilent Technologies from $170.00 to $155.00 and set an “outperform” rating on the stock in a report on Wednesday, February 23rd. Robert W. Baird increased their price target on shares of Agilent Technologies from $155.00 to $161.00 and gave the company an “outperform” rating in a research report on Wednesday. Cowen dropped their price target on shares of Agilent Technologies from $187.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 23rd. Stifel Nicolaus dropped their target price on shares of Agilent Technologies from $169.00 to $145.00 and set a “hold” rating for the company in a research report on Wednesday, February 23rd. Finally, Citigroup dropped their target price on shares of Agilent Technologies from $190.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, February 23rd. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $163.08.

Agilent Technologies Company Profile (Get Rating)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.

Featured Articles

Earnings History for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.